ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,331.50
-0.26%
S&P ASX All Technology
3,865.00
0.36%
Brent Oil
73.325
-0.16%
US Dollar vs AUD
1.55984
-0.43%
Bitcoin
100,842.21
-0.35%
Pepperstone
Advertisement
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. ChromaDex Corporation (CDXC) Share Price

ChromaDex Corporation

ChromaDex Corporation (CDXC)

NASDAQ
6.45
-0.26
(-3.87%)
Closed 12 December 8:00AM
Delayed by 15 minutes
6.80
0.35
(5.43%)
After Hours: 10:53AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
6.80
Bid
6.45
Offer
6.90
Volume
525,733
6.45 Day's Range 6.81
1.32 52 Week Range 7.9738
Market Cap
519.406M
Previous Close
6.71
Open
6.75
Last Trade
45
@
6.4801
Last Trade Time
Financial Volume
US$ 3,470,915
VWAP
6.602
Average Volume (3m)
1,268,928
Shares Outstanding
76,383,267
Dividend Yield
-
PE Ratio
-99.85
Earnings Per Share (EPS)
-0.06
Revenue
83.57M
Net Profit
-4.94M

About ChromaDex Corporation

ChromaDex Corp is a bioscience company dedicated to healthy aging. The ChromaDex team is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship in... ChromaDex Corp is a bioscience company dedicated to healthy aging. The ChromaDex team is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex's patent portfolio. It delivers Niagen as the sole active ingredient in its consumer product namely, Tru Niagen which is available on Tru Niagen's website and through partnerships with retailers and distributors. Show more

Sector
Medicinal Chems,botanicl Pds
Industry
Medicinal Chems,botanicl Pds
Website
www.chromadex.com
Headquarters
Dover, Delaware, USA
Founded
-
ChromaDex Corporation is listed in the Medicinal Chems,botanicl Pds sector of the NASDAQ with ticker CDXC. The last closing price for ChromaDex was US$6.71. Over the last year, ChromaDex shares have traded in a share price range of US$ 1.32 to US$ 7.9738.

ChromaDex currently has 76,383,267 shares in issue. The market capitalisation of ChromaDex is US$512.53 million. ChromaDex has a price to earnings ratio (PE ratio) of -99.85.

Ask ADVFN Intelligence (AI)

CDXC Latest News

More News

Form 8-K - Current report

05 December 2024
Edgar (US Regulatory)

ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category

ChromaDex Corp. (NASDAQ:CDXC) proudly announces its inclusion on the Inc. 2024 Best in Business list in the Health Products category. Inc.’s annual Best in Business Awards celebrate the...

04 December 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

25 November 2024
Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]

22 November 2024
Edgar (US Regulatory)

Form 8-K - Current report

22 November 2024
Edgar (US Regulatory)

ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement

The gold standard in NAD+ supplementation, Niagen® is a key ingredient for supporting cellular health and promoting healthy aging in Longevity.Technology’s new supplement ChromaDex Corp. (NASDAQ:...

15 November 2024
Business Wire

Form 3 - Initial statement of beneficial ownership of securities

09 November 2024
Edgar (US Regulatory)

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide

National rollout provides enhanced accessibility to Niagen IV, a significant advancement in NAD+ IV therapy ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine...

08 November 2024
Business Wire

ChromaDex Corporation Reports Third Quarter 2024 Financial Results

Total net sales of $25.6 million, up $6.1 million or 31% year-over-year, gross margin of 63.5% and record net income and adjusted EBITDA of $1.9 million and $2.9 million, respectively, for the...

01 November 2024
Business Wire

Form 8-K - Current report

01 November 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.765-10.11235955067.5657.7866.457116316.8026282CS
4-0.548-7.457811649437.3487.97386.458352897.25430887CS
123.407100.4126142063.3937.97383.1812689285.99536521CS
263.72120.7792207793.087.97382.3057888465.22028014CS
525.41389.2086330941.397.97381.325158114.71727247CS
1562.4255.25114155254.387.97381.153475773.37301214CS
2602.9677.08333333333.8423.661.155418138.08616829CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LAESSEALSQ Corporation
US$ 1.1406
(99.75%)
225.46M
AMPGAmplitech Group Inc
US$ 1.9001
(91.52%)
201.88M
CADLCandel Therapeutics Inc
US$ 7.7401
(67.90%)
100.61M
JZXNJiuzi Holdings Inc
US$ 1.792
(60.00%)
2.56M
LDTCLeddarTech Holdings Inc
US$ 1.81
(49.59%)
75.14M
SFHGSamfine Creation Holdings Group Ltd
US$ 3.04
(-85.59%)
10.2M
CLRBCellectar Biosciences Inc
US$ 0.3039
(-76.26%)
37.51M
QTTBQ32 Bio Inc
US$ 6.0291
(-75.30%)
3.39M
TFFPTFF Pharmaceuticals Inc
US$ 0.1639
(-45.78%)
3.47M
MARXMars Acquisition Corporation
US$ 7.24
(-33.33%)
54.57k
RGTIRigetti Computing Inc
US$ 7.38
(13.71%)
313.25M
LAESSEALSQ Corporation
US$ 1.1406
(99.75%)
225.46M
AMPGAmplitech Group Inc
US$ 1.9001
(91.52%)
201.88M
NVDANVIDIA Corporation
US$ 139.31
(3.14%)
184.91M
LCIDLucid Group Inc
US$ 2.44
(3.39%)
111.23M

CDXC Discussion

View Posts
TrendTrade2016 TrendTrade2016 1 month ago
CDXC 7 DOLLA BREAK...BEAST
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
cdxc heres 7 bucks
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
CDXC HERE COMES 7 BUCKS
👍️0
tredenwater2 tredenwater2 1 month ago
Amazing how you and your buddies show up here in a similar fashion and are just abead of robust MC increases after years of decline. You must be friends with or connected to HF managers that “get a little loose” after a few drinks.

The stories my brother shared, and others, about this are true.
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
CDXC MONSTER BREAK OUT
👍️0
gail gail 1 month ago
congrats!
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
CDXS HEREW W E GO
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
CDXS NEW 52 WEEK HIGH
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
HERE WE GO...BREAKING NEW 52 WEEK HIGH
👍️0
PonkenPlonken PonkenPlonken 1 month ago
The GRAS status allows it to be incorporated into conventional foods and beverages.
Most people arent biohacking fanatics.
Ty for mentioning NMN -- ill take a second look.
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
THE NAD SPACE DOES NOT NEED FDA...BUT THIS IS THE ONLY PUBLIC NAD PLAY....NNM NOW BEING ALL THE RAGE!!
👍️0
PonkenPlonken PonkenPlonken 1 month ago
The competition is behind as CDXC has FDA safety review = "Generally recognized as safe" (GRAS) status + they have the patents.
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
COMPANY HAS COMPETION NOW IN THE NAD SPACE...SO JUST A TRADE
👍️0
PonkenPlonken PonkenPlonken 1 month ago
You are right. If they change the apathic share-selling management that practically - for whatever reason - kept the trial results hidden from the public, this can go far.
Imagine the health and longevity influencers catching on. No media on this for now.
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
CDXC LETS ROLL...COMPANY HAS THE NAD KING!!
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
CDXC HOLDING STRONG
👍️0
gail gail 1 month ago
it tried to anyway. lol
👍️0
gail gail 1 month ago
nice grab, its moving up now.
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
GRABBED THIS DIP....LOVE THIS COMPANY!!!
👍️0
Monksdream Monksdream 1 month ago
CDXC, new 52=week high
👍️0
Monroe1 Monroe1 1 month ago
Back in the green. Good company with a great product and huge demand building.
👍️0
Monksdream Monksdream 3 months ago
CDXC under $4
👍️0
Tiger Money Tiger Money 4 months ago
I have only added to my position here and plan on selling some at $25
👍️0
Sirpeter Sirpeter 4 months ago
Good call huh?
👍️0
Tiger Money Tiger Money 4 months ago
Agreed
👍️0
Sirpeter Sirpeter 4 months ago
Keep it now...I'm sticking with options in ABT, WDC and UBER...have some HUMA shares too...this will work also...Its in the Russell 2000 will be good with rate cuts...like both
👍️0
Tiger Money Tiger Money 4 months ago
Haven’t sold yet. U were confident and I’m confident in you!
👍️0
Sirpeter Sirpeter 4 months ago
Lol
👍️0
Tiger Money Tiger Money 4 months ago
I bought a bunch of huma yday. It will be a $25-50 stock as soon as the fda pulls its heads out of its asses
👍️0
Sirpeter Sirpeter 4 months ago
Dumped it...like Huma better
👍️0
Sirpeter Sirpeter 4 months ago
Still confident this will run soon...don't sell
👍️0
Tiger Money Tiger Money 4 months ago
I like the plan, thanks
👍️0
Sirpeter Sirpeter 4 months ago
Not enough improvement in the 2nd qtr to move the needle here yet...will hold it for a week and see what happens
👍️0
Sirpeter Sirpeter 4 months ago
Fingers crossed
👍️0
Tiger Money Tiger Money 4 months ago
I don’t plan on selling any ahead of time. I think I have about $4k in this one
👍️0
Sirpeter Sirpeter 4 months ago
This is a high risk reward play for now...will know tomorrow if got it right
👍️0
Tiger Money Tiger Money 4 months ago
Thanks! Trying to h to get caught up in this bloodbath
👍️0
Sirpeter Sirpeter 4 months ago

Gm Tiger
Earnings call here Weds...may not be good this qtr because of the major product roll-out...that's expensive... will still hold this one. not holding much else during this sell off...tech and bio will be good when it's over
👍️0
Tiger Money Tiger Money 4 months ago
Thanks. Crazy times in the markets!
👍️0
Sirpeter Sirpeter 4 months ago
Im still holding calls on all these...its a bit early for this one but it will come based on the valuation...most likely in the next qtr...hang in there...in the meantime I've been cleaning up over at ABT...also still waiting on PFE to go...all on positive guidence and Q reports...mkt down today on weak job numbers...its summer what do they expect?
👍️0
Tiger Money Tiger Money 4 months ago
Why has this been shorting the bed the last two weeks minus today’s market bloodbath? Add more or is it going to keep dropping? Thanks
👍️0
Tiger Money Tiger Money 5 months ago
Awesome, thanks!
👍️0
Sirpeter Sirpeter 5 months ago
Eventually about $10...so far I own 30 Nov calls...may add to them
👍️0
Tiger Money Tiger Money 5 months ago
Thanks! Price target?
👍️0
Sirpeter Sirpeter 5 months ago
Mass distribution of Niagen a suppliment that helps to extend life...lots of news under the news heading
👍️0
Tiger Money Tiger Money 5 months ago
Why do you feel so strong about this one? Thanks
👍️0
Tiger Money Tiger Money 5 months ago
I need to buy a couple thousand shares if I can remember tmrw! Work has been so busy!
👍️0
Sirpeter Sirpeter 5 months ago
Starting...
👍️0
Sirpeter Sirpeter 5 months ago
This one is starting...I alerted you
👍️0
Monksdream Monksdream 5 months ago
CDXC under $3
👍️0

Your Recent History

NASDAQ
CDXC
ChromaDex
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved